I presented three real-world evidence (RWE) abstracts mdanderson at #ESMO24. Those RWE identify unmet clinical needs and set bench marks for efficacy evaluation, which are critical initial steps for drug development. ESMO - European Society for Medical Oncology 👉 In the HER2 NSCLC RWE analysis (n=589), we found that most oncogenic mutations are in the HER2 kinase domain. The 1L therapy mPFS for those patients was only 5.5 months and OS 16.0 months, therefore, new targeted therapies are needed. Boehringer Ingelheim Bayer Gerrina Ruiter Dominik Ruettinger 👉 In the MET NSCLC RWE analysis (n=456), we found MET over expression (OE) occurs in 20-25% of NSCLC. MET OE high NSCLC patients had a significantly shorter time to next treatment (TTNT) than MET OE low/no patients, this identified a major unmet need to improve MET OE patient's outcome. AbbVie Olga Ryan 👉 In the EGFR uncommon mutation RWE analysis (n=3,276), many EGFR PACC mutation patients are still receiving chemo-IO with PFS only at 4.2 months, and osimertinib with PFS at 6.0 months, we need better precision oncology practice and designed TKI for EGFR PACC mutations. Dr. Elizabeth Buck Black Diamond Therapeutics Sergey Yurasov
The ESMO - European Society for Medical Oncology Congress 2024, held in Barcelona from September 13 to 17, gathered over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives. Organized by the European Society for Medical Oncology (ESMO), the event showcased valuable insights shared by attendees on social media. Vivek Subbiah, MD Andrea Botticelli Ravindran Kanesvaran Penilla Gunther Winan van Houdt SIOP Europe, the European Society for Paediatric Oncology (SIOPE) SIOG - International Society of Geriatric Oncology FRANCESCA SPADA Myriam Chalabi Prof. Dr. med. Sabine D. Brookman-May Ibrahim Halil Sahin Jarushka Naidoo Iván R González Chandler Park, M.D., F.A.C.P. Paolo Tarantino Arun Azad Matteo Lambertini Stephen Liu Shilpa Gupta, MD Tian Zhang Stephanie Graff, MD, FACP, FASCO Joaquim Bellmunt Xiuning Le https://lnkd.in/ephXuCkg #BreastCancer #OncoDaily #Oncology #Cancer #Health #Medicine #ESMO24
Tanja Obradovic
1mo
Absolutely in agreement with point made that patients with EGFR PACC mutation have truly large need.
Amazing! Congrats, friend!
Xiaochuan Zhou
1mo
Very helpful
So grateful for these studies to help move ahead science and improve outcomes for our lung cancer patient community. Precision medicine is getting ever more precise. That’s better for patients.